Hydrix Limited (HYD) AI Stock Analysis

• Market Cap: AU$3.82M
• Dividend Yield: N/A
• Average Volume (3M): 316.59K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.07
• Revenue Growth: -4.86%
• EPS Growth: 64.36%
• Country: AU
• Employees: 55
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): -0.01
• Shares Outstanding: 272,768,860
• 10 Day Avg. Volume: 341,547
• 30 Day Avg. Volume: 316,588
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Hydrix Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and negative profitability metrics. The technical analysis further supports a bearish outlook with oversold conditions and downward trends. Valuation metrics also reflect challenges, with a negative P/E ratio and no dividend yield.

Hydrix Limited Business Overview & Revenue Model

Company Description

Hydrix Limited provides product design, engineering, and regulatory services in Australia, Singapore, Europe, North America, and internationally. It operates through two segments: Hydrix Services and Hydrix Medical. It provides cardiovascular products, such as The GUARDIAN, a cardiac monitoring and alerting device that reduces the stresses of living; Phyzhon PHYRARI FFR-Wire enables cardiologists to combine diagnosis procedures with delivery of therapy including stents; and LUDO, a customizable plug-and-play platform that provides critical tools to start MCS pump development. The company also offers a range of services, including product development, regulatory and clinical consulting, and technology commercialization. It serves medical, consumer, industrial, utilities, defense, aerospace, and mining industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia

How the Company Makes Money

Hydrix Limited generates revenue through multiple streams, primarily by selling its medical devices and software solutions to hospitals, clinics, and healthcare providers. The company also earns income from engineering services, which include product development and consulting for third-party clients in the medical field. Additionally, Hydrix may establish partnerships with other healthcare technology firms to co-develop products or share expertise, further contributing to its revenue. The company's ability to secure contracts and maintain relationships with key stakeholders in the healthcare industry is crucial for its financial performance.

Hydrix Limited Financial Statement Overview

Summary

Hydrix Limited's financial performance reflects significant challenges, with declining revenue, negative profit margins, and high leverage. The balance sheet is weak with negative stockholders' equity, and cash flow issues persist despite positive financing cash flow.

Income Statement

Hydrix Limited's income statement indicates financial challenges, with declining revenue and negative profit margins. The company reported a significant net loss, and both EBIT and EBITDA margins are negative, reflecting operational inefficiencies. The revenue growth rate is negative, showing a downward trend in sales.

Balance Sheet

The balance sheet reveals a precarious financial position, with negative stockholders' equity indicating potential solvency issues. The high debt-to-equity ratio highlights significant leverage, increasing financial risk. The equity ratio is also negative, suggesting that liabilities exceed assets.

Cash Flow

Cash flow analysis shows persistent negative free cash flow, indicating the company is not generating sufficient cash to cover its capital expenditures. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. However, some relief is provided by positive financing cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.32M	10.09M	10.61M	13.16M	10.33M	7.45M
Gross Profit	9.68M	9.53M	9.79M	-638.73K	-3.31M	-6.46M
EBITDA	-2.50M	-1.40M	-7.92M	1.30M	-4.05M	-6.34M
Net Income	-6.40M	-2.92M	-9.56M	-396.93K	-5.55M	-9.78M
Balance Sheet
Total Assets	9.09M	8.35M	8.62M	14.58M	15.94M	19.38M
Cash, Cash Equivalents and Short-Term Investments	1.12M	297.88K	914.27K	1.15M	1.94M	6.65M
Total Debt	7.61M	7.98M	7.61M	4.73M	5.40M	5.97M
Total Liabilities	12.89M	14.39M	11.98M	8.22M	12.66M	13.67M
Stockholders Equity	-3.79M	-6.04M	-3.36M	6.35M	3.28M	5.71M
Cash Flow
Free Cash Flow	-367.89K	-535.13K	-1.91M	-3.32M	-6.75M	-3.35M
Operating Cash Flow	-359.81K	-527.01K	-1.89M	-3.12M	-6.58M	-2.86M
Investing Cash Flow	157.07K	-54.20K	-53.43K	-209.71K	-306.65K	-641.56K
Financing Cash Flow	471.87K	-36.31K	1.71M	2.16M	1.72M	7.53M

Hydrix Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HYD, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 18.31 is Positive, neither overbought nor oversold. The STOCH value of 29.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HYD.

Hydrix Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
DVL	53 Neutral	AU$57.40M	―	-78.66%	―	-13.40%	4.76%
KNO	46 Neutral	AU$6.27M	47.78	-23.31%	―	2.15%	-900.00%
HYD	41 Neutral	AU$3.82M	―	-637.73%	―	-4.86%	64.36%
X2M	39 Underperform	AU$13.17M	―	-1370.92%	―	-51.64%	-21.74%
SIS	39 Underperform	AU$6.43M	―	―	―	-26.58%	―
BCC	38 Underperform	AU$8.21M	―	-135.89%	―	-21.60%	-657.00%

Hydrix Limited Corporate Events

Hydrix Limited Reports Strong June Quarter with Increased Sales and Contract Wins

Hydrix Limited announced a positive trading update for the June quarter, highlighting increased sales activity and recent contract wins that support near-term growth. The company reported $2.4 million in quarterly revenues, with significant contributions from cardiac and medtech products and emerging growth from defense clients. Hydrix secured 18 new and existing client contracts totaling $3.5 million in revenues and has 20 active clients with a potential future project revenue base of $40 million. Despite a $0.76 million operating loss, this marks a 45% improvement from the previous corresponding period, indicating a positive trend and potential for further revenue momentum in the coming months.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 472,402 securities due to the expiry of options without exercise or conversion as of June 30, 2025. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 264,751 securities due to the expiry of options or other convertible securities without exercise or conversion as of June 30, 2025. This update on the company’s issued capital may impact stakeholders by potentially altering the company’s financial structure and market positioning, reflecting a strategic decision in managing its securities.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 3,750 securities, specifically options expiring on June 30, 2029, due to unmet conditions. This development may impact the company’s financial strategies and stakeholder interests, as it reflects on the company’s ability to meet certain operational conditions.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 10,800 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation, effective June 30, 2025, may impact the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 9,450 securities due to the lapse of conditional rights, as the conditions were not met by the deadline of June 30, 2025. This cessation could impact the company’s capital structure and may influence stakeholder perceptions of its financial health and strategic direction.